Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial registered on ANZCTR
Registration number
ACTRN12624001171505p
Ethics application status
Not yet submitted
Date submitted
23/08/2024
Date registered
25/09/2024
Date last updated
25/09/2024
Date data sharing statement initially provided
25/09/2024
Type of registration
Prospectively registered
Titles & IDs
Public title
Effectiveness of zinc supplementation as an adjunct therapy in managing idiopathic pulmonary fibrosis
Query!
Scientific title
Evaluating the effect of zinc supplementation on lung function in idiopathic pulmonary fibrosis: RCT
Query!
Secondary ID [1]
312808
0
None
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Idiopathic Pulmonary Fibrosis
334875
0
Query!
Condition category
Condition code
Respiratory
331429
331429
0
0
Query!
Other respiratory disorders / diseases
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Zinc gluconate, 30 mg will be administered as a daily oral tablet for 12 months. Adherence will be monitored through tablet returns, where participants will be given a bottle each month, and the remaining pills will be counted at each visit to assess compliance with the treatment regimen.
Query!
Intervention code [1]
329346
0
Treatment: Drugs
Query!
Comparator / control treatment
Maltodextrin tablet
Query!
Control group
Placebo
Query!
Outcomes
Primary outcome [1]
339183
0
Lung function
Query!
Assessment method [1]
339183
0
Spirometry assessment of Forced vital capacity (FVC; measured as a percentage of predicted value) among IPF patients
Query!
Timepoint [1]
339183
0
FVC will be measured at baseline, 6 months, and 12 months (primary timepoint) post-baseline
Query!
Secondary outcome [1]
438972
0
Pulmonary hypertension
Query!
Assessment method [1]
438972
0
Echocardiographic assessment of pulmonary arterial pressure
Query!
Timepoint [1]
438972
0
Baseline and every 6 months over 12 months post-baseline
Query!
Secondary outcome [2]
438973
0
Number of acute exacerbations
Query!
Assessment method [2]
438973
0
Physician review and chest X-ray assess for the presence of parenchymal abnormalities in lung tissue without signs of collapsed lungs (pneumothorax) or fluid around the lungs (pleural effusion) since the last visit
Query!
Timepoint [2]
438973
0
Baseline and every 3 months over 12 months post-baseline
Query!
Secondary outcome [3]
439201
0
Number of acute exacerbations days
Query!
Assessment method [3]
439201
0
Physician evaluation and chest X-ray to assess for parenchymal abnormalities in lung tissue, while ensuring there are no signs of lung collapse (pneumothorax) or fluid accumulation around the lungs (pleural effusion) since the last visit.
Query!
Timepoint [3]
439201
0
Baseline and every 3 months over 12 months post-baseline
Query!
Eligibility
Key inclusion criteria
Patients 40 years of age or older who have received a diagnosis of IPF according to 2022 international guidelines and confirmed by a multidisciplinary team.
Query!
Minimum age
40
Years
Query!
Query!
Maximum age
80
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
IPF patients with severe co-existing medical conditions as determined by the investigators such as but not limited to advanced cardiovascular diseases, uncontrolled diabetes, or malignancies.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Numbered containers
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Permuted block randomisation
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Query!
Other design features
Query!
Phase
Not Applicable
Query!
Type of endpoint/s
Efficacy
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Not yet recruiting
Query!
Date of first participant enrolment
Anticipated
2/06/2025
Query!
Actual
Query!
Date of last participant enrolment
Anticipated
30/07/2027
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
Query!
Sample size
Target
130
Query!
Accrual to date
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
SA
Query!
Funding & Sponsors
Funding source category [1]
317242
0
Self funded/Unfunded
Query!
Name [1]
317242
0
Query!
Address [1]
317242
0
Query!
Country [1]
317242
0
Query!
Primary sponsor type
University
Query!
Name
University of Adelaide
Query!
Address
Query!
Country
Australia
Query!
Secondary sponsor category [1]
319523
0
None
Query!
Name [1]
319523
0
Query!
Address [1]
319523
0
Query!
Country [1]
319523
0
Query!
Ethics approval
Ethics application status
Not yet submitted
Query!
Ethics committee name [1]
315980
0
Central Adelaide Local Health Network HREC
Query!
Ethics committee address [1]
315980
0
https://www.rah.sa.gov.au/research/for-researchers/central-adelaide-local-health-network-human-research-ethics-committee
Query!
Ethics committee country [1]
315980
0
Australia
Query!
Date submitted for ethics approval [1]
315980
0
03/03/2025
Query!
Approval date [1]
315980
0
Query!
Ethics approval number [1]
315980
0
Query!
Summary
Brief summary
The proposed study investigates zinc's impact on lung function, IPF-related complications including pulmonary hypertension, and acute exacerbation in IPF. The findings will establish a rationale for incorporating zinc into IPF management and lay the foundation for further research into zinc status monitoring in existing IPF care protocols.
Query!
Trial website
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
136414
0
Dr Patrick Asare
Query!
Address
136414
0
University of Adelaide Ahms Building level 7, North Terrace-Adelaide, South Australia 5000.
Query!
Country
136414
0
Australia
Query!
Phone
136414
0
+61 410346185
Query!
Fax
136414
0
Query!
Email
136414
0
[email protected]
Query!
Contact person for public queries
Name
136415
0
Patrick Asare
Query!
Address
136415
0
University of Adelaide Ahms Building level 7, North Terrace-Adelaide, South Australia 5000
Query!
Country
136415
0
Australia
Query!
Phone
136415
0
+61 410346185
Query!
Fax
136415
0
Query!
Email
136415
0
[email protected]
Query!
Contact person for scientific queries
Name
136416
0
Patrick Asare
Query!
Address
136416
0
University of Adelaide Ahms Building level 7, North Terrace-Adelaide, South Australia 5000
Query!
Country
136416
0
Australia
Query!
Phone
136416
0
+61 410346185
Query!
Fax
136416
0
Query!
Email
136416
0
[email protected]
Query!
Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No
Query!
No/undecided IPD sharing reason/comment
Query!
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
Documents added manually
No documents have been uploaded by study researchers.
Documents added automatically
No additional documents have been identified.
Download to PDF